

CATALYST PHARMACEUTICALS, INC.

Form 8-K/A

August 07, 2015

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K/A**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d)**

**OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of Earliest Event Reported): March 23, 2015**

**CATALYST PHARMACEUTICALS, INC.**

**(Exact Name Of Registrant As Specified In Its Charter)**

**Delaware**  
**(State or other jurisdiction**

**of incorporation)**

**001-33057**  
**(Commission**

**File Number)**

**76-0837053**  
**(I.R.S. Employer**

**Identification No.)**

**355 Alhambra Circle**

**Suite 1500**

**Coral Gables, Florida**  
**(Address of principal executive offices)**

**33134**  
**(Zip Code)**

**Registrant's telephone number, including area code: (305) 529-2522**

**Not Applicable**

**Former Name or Former address, if changed since last report**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 1.01 Entry Into a Material Definitive Agreement**

On March 23, 2015, Catalyst Pharmaceutical Partners, Inc., now known as Catalyst Pharmaceuticals, Inc. (the Company ) and CPT 355 Alhambra Circle, LLC entered into that certain Third Amendment to Lease Agreement, and on March 27, 2015, the Company filed a Form 8-K reporting that it had entered into the new lease. The March 27, 2015 Form 8-K included a copy of the new lease as an exhibit, portions of which were omitted and filed separately with the U.S. Securities and Exchange Commission (SEC ) pursuant to a request for confidential treatment.

This Form 8-K/A amends the Company's Form 8-K filed on March 27, 2015 to state in the list of exhibits that portions of this exhibit have been omitted and filed separately with the SEC pursuant to a request for confidential treatment.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

- 10.1 Third Amendment to Lease, dated effective as of March 16, 2015, between the Company and CPT 355 Alhambra Circle, LLC (portions of this exhibit have been omitted and filed separately with the SEC pursuant to a request for confidential treatment.)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Catalyst Pharmaceuticals, Inc.**

By: /s/ Alicia Grande  
Alicia Grande  
Vice President, Treasurer and CFO

Dated: August 7, 2015